🇺🇸 Qvar in United States

FDA authorised Qvar on 3 August 2017 · 9,780 US adverse-event reports

Marketing authorisation

FDA — authorised 3 August 2017

  • Application: NDA207921
  • Marketing authorisation holder: NORTON WATERFORD
  • Status: supplemented

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Dyspnoea — 1,789 reports (18.29%)
  2. Asthma — 1,617 reports (16.53%)
  3. Drug Ineffective — 1,241 reports (12.69%)
  4. Cough — 1,082 reports (11.06%)
  5. Headache — 772 reports (7.89%)
  6. Fatigue — 749 reports (7.66%)
  7. Nausea — 648 reports (6.63%)
  8. Wheezing — 646 reports (6.61%)
  9. Malaise — 620 reports (6.34%)
  10. Pain — 616 reports (6.3%)

Source database →

Other Respiratory/Pulmonology approved in United States

Frequently asked questions

Is Qvar approved in United States?

Yes. FDA authorised it on 3 August 2017.

Who is the marketing authorisation holder for Qvar in United States?

NORTON WATERFORD holds the US marketing authorisation.